Humira, Hulio, Amgevita, Hyrimoz, Idacio, Imraldi ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	2

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001793-28-NL (EUCTR)	05/11/2019	05/11/2019	Adalimumab dose reduction aiming low drug levels with control of disease activity (ADDORA-LOW)	Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial - ADDORA-Low	Rheumatoid arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Humira, Hulio, Amgevita, Hyrimoz, Idacio, Imraldi Product Name: Adalimumab Product Code: D2E7 INN or Proposed INN: ADALIMUMAB	Reade	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	89	Phase 4	Netherlands
2	EUCTR2019-001554-25-NL (EUCTR)	29/10/2019	29/10/2019	Adalimumab dose optimization in rheumatoid arthritis using drugconcentration in blood (ADDORA): multi-center open label randomizedcontrolled trail	Adalimumab dose optimization in rheumatoid arthritis using therapeuticdrug monitoring (ADDORA): multi-center open label randomized controlledtrail - ADalimumab Dose Optimization in Rheumatoid Arthritis using (ADDORA)	Rheumatoid arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Humira, Hulio, Amgevita, Hyrimoz, Idacio, Imraldi Product Name: Adalimumab Product Code: D2E7 INN or Proposed INN: ADALIMUMAB	Reade	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	267	Phase 1;Phase 4	Netherlands